Key points from article :
LEAF's Steve Hill interviews Kelsey Moody, CEO of Ichor Therapeutics.
$16 million raised in 2018 allowing company to scale up all aspects of operations.
He can’t talk about the progress on FoxBio, except that he's very bullish.
Antoxerene platform can build large proteins on a scale suitable for drug screening.
Using platform to investigate senolytics and partner with pharmaceutical companies.
Will spin out contract research services into a separate entity, Ikaria Life Sciences.
People will understand that ageing is malleable and susceptible to intervention.
